US Medical Aesthetics Market

The US medical aesthetics market is projected to reach USD 17.45 billion by 2031 from USD 9.46 billion in 2026, at a CAGR of 13.0% during the forecast period. The medical aesthetics industry in the US is significantly influenced by several factors, including increasing consumer preference for minimally invasive procedures, the impact of social media, an aging population, and rising disposable incomes. Strict regulations in the US are also boosting consumer confidence in various treatments, including injectables (such as botulinum toxin and dermal fillers), energy-based devices (like lasers, radiofrequency, and ultrasound), and body contouring procedures. Together, these treatments account for about 55% of the procedure volume due to their low downtime and high effectiveness.

The US boasts one of the most advanced clinical infrastructures in the world, along with a high concentration of board-certified physicians that support its medical aesthetics market. Key factors contributing to the rapid adoption of aesthetic procedures include a continuous influx of new technologies, such as AI-driven personalization and the integration of various therapies, as well as a widespread network of medical centers and clinics. Additionally, the growing willingness among the US population to undergo elective aesthetic procedures, paired with the accelerated commercialization of new treatments, is expected to drive market growth in the coming years.

To know about the assumptions considered for the study download the pdf brochure

Key players in the US medical aesthetics market include AbbVie Inc. (US), Galderma (Switzerland), Johnson & Johnson (US), Bausch Health Companies, Inc. (Canada), and Cutera, Inc. (US), among others. The major growth strategies adopted by leading companies in this market include product approvals and launches, acquisitions, collaborations, partnerships, and agreements. Over the past three years, product approvals and launches have been the most popular organic growth strategies among market players seeking to increase their market share. 

AbbVie Inc. (US):

AbbVie Inc. is a global biopharmaceutical company that has established a strong presence in the US medical aesthetics market following its 2020 acquisition of Allergan. The company’s primary products include Botox, Juvéderm dermal fillers, and CoolSculpting, which together address various aspects of facial rejuvenation, volume loss, and body contouring. AbbVie aims to expand its presence in the US by leveraging strategic acquisitions and partnerships to enter new markets. Innovation is central to the company’s strategy; it has invested significantly in research and development to enhance the effectiveness and longevity of aesthetic treatments. Additionally, AbbVie focuses on consumer education and brand recognition through both traditional and digital marketing channels. The company is committed to complying with regulations in all US markets where it operates, ensuring the safety and quality of its products. By making environmentally responsible choices and demonstrating social responsibility, AbbVie aims to strengthen its position in the competitive US medical aesthetics industry.

Galderma (Switzerland):

Galderma is a leading dermatology company with a significant presence in the US medical aesthetics market. Its extensive portfolio includes well-known brands such as Restylane (dermal fillers), Azzalure (botulinum toxin), and Sculptra (collagen biostimulator), all designed to rejuvenate the skin and add volume. The company’s strategy in the US focuses on constant innovation and ongoing research and development, leading to new formulations and expanded uses for existing products. To strengthen its position in the injectable sector, Galderma has made key expansions, including the acquisition of Q-Med, the maker of Restylane. The company prioritizes product safety and regulatory compliance, ensuring alignment with the US’s stringent regulations. Additionally, Galderma invests in consumer education and professional training to uphold high-quality treatment standards. Driven by a commitment to sustainability, Galderma integrates environmental stewardship into all its operations. Its strategic initiatives, including gradual regional expansion, partnerships, and consumer engagement, have established Galderma as a trustworthy and reliable leader in the US medical aesthetics market.

Johnson & Johnson (US):

Johnson & Johnson (J&J) is a significant player in the US medical aesthetics market through its Ethicon division, which offers products like Voluma (a dermal filler) and Botox. The company is dedicated to continuous innovation and allocates substantial resources to R&D to enhance its aesthetic treatments and expand their application. J&J's strategy involves not only maintaining a strong presence in the US market but also adapting to regional regulations and consumer preferences. The company strengthens its market position through strategic acquisitions and partnerships with clinics and practitioners. To ensure compliance with US regulations and build consumer trust, J&J enforces strict safety and quality standards for its products. Additionally, the company conducts training programs and awareness campaigns for both consumers and professionals as part of its product adoption strategy. In line with its commitment to sustainability, J&J implements environmentally friendly practices across the organization to meet the growing demand for green products. This approach solidifies J&J’s position at the forefront of the highly competitive US medical aesthetics market.

Market Ranking:

The US medical aesthetics market is aided by the strong presence of popular companies like AbbVie (Allergan Aesthetics), which is the market leader, with a commanding market position based on its robust brand portfolio, global distribution footprint, and R&D investment. Galderma Pharma S.A., Merz Aesthetics, and others follow, respectively. Each of these leaders sustains their success through innovation (e.g., new formulations, new indications based on clinical evidence), continuing data on product efficacy and safety, and building trust with both healthcare providers and consumers. The top three players dismiss their competition by leveraging strong brands (e.g., Juvéderm, Restylane, Belotero), substantial R&D investment, and extensive distribution networks.

The remaining share of the market is fragmented, comprising legacy mid-tier businesses and a mix of smaller or regional manufacturers. While offering innovative products and regional strength, these companies have far less impact as individual companies and must compete on price, offering a specialization, or leveraging local relationships. 

Related Reports:

US Medical Aesthetics Market by Product (Botox, Filler, Peel, Liposuction, Microneedling, Hair Removal, Laser Resurfacing, RF), Device type (Multimodal, At-home), Procedure (Surgical, Nonsurgical), End User (Hospital, Beauty Clinic, Spa) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]